Dr. Martin Kolb

Martin Kolb

MD, PhD

Professor, Division of Respirology, Department of Medicine

Pathology & Molecular Medicine; St. Joseph’s Healthcare, Firestone Institute for Respiratory Health

 

Education and Professional Standing

Research Interests

Dr. Kolb’s major research area is focused on mechanisms of lung injury, repair and fibrosis, particularly in Idiopathic Pulmonary Fibrosis (IPF). He has a strong interest in growth factor biology (e.g. TGFβ and IL-1), extracellular matrix, and mesenchymal cell progenitors (mesenchymal stem cells and fibrocytes). In his lab he uses a variety of animal models to study disease mechanisms and also the efficacy of novel drugs in the preclinical setting. Further, Dr. Kolb leads activities in biomarker development for lung fibrosis and he participates as Principal Investigator and Steering Committee members in numerous clinical trials on interstitial lung disease.

Dr. Kolb has over 100 peer-reviewed publications in journals such as New England Journal of Medicine, Journal of Clinical Investigation, American Journal of Pathology, American Journal of Respiratory and Critical Care Medicine, Journal of Immunology, European Respiratory Journal and many others. He is/was funded by CIHR, NIH, CFI, OTS and different Pharma companies over the years. He has received career awards from the Parker B. Francis Families Foundation, the Department of Medicine at McMaster and the New Investigator Award from the Canadian Institute for Health Research.

Clinical Activities

Dr. Kolb looks after several hundred patients with interstitial lung disease in his specialty clinic and also practices in General Respirology. He is medical staff at St. Joseph’s Healthcare Hamilton for Respirology and General Internal Medicine. Clinic bookings can be made through extension x34144.

Other Activities

Dr. Kolb is Associate Editor for Thorax and Deputy Editor for Respirology, the official journals of the British Thoracic Society and the Asian Pacific Society of Respirology. He is on the Editorial Boards of the American Journal of Respiratory and Critical Care Medicine, the American Journal of Respiratory Cell and Molecular Biology and European Respiratory Journal, which are all amongst the top ranked journals in Respiratory Medicine. Dr. Kolb is Chair of the Lung Injury and Repair Group of the European Respiratory Society. He was also Chair of the last International Colloquium on Lung and Airway Fibrosis, the leading international conference in lung fibrosis.

Recent Publications

  1. Froese AR, Shimbori C, Bellaye PS, Ask K, Inman M, Obex S, Fatima S, Jenkins G, Gauldie J, Kolb M. Stretch Induced Activation of TGF-β1 in Pulmonary Fibrosis. Am J Respir Crit Care Med. epub Jan 2016
  2. Knippenberg S, Ueberberg B, Maus R, Bohling J, Ding N, Tort Tarres M, Hoymann HG, Jonigk D, Izykowski N, Paton JC, Ogunniyi AD, Lindig S, Bauer M, Welte T, Seeger W, Guenther A, Sisson TH, Gauldie J, Kolb M*, Maus UA*. Streptococcus pneumoniae triggers progression of pulmonary fibrosis through pneumolysin. Thorax. 2015 Jul;70(7):636-46. [* joint last authorship]
  3. Luo Y*, Xu W*, Chen H, Warburton D, Dong R, Qian B, Selman M, Gauldie J, Kolb M, Shi W. A novel profibrotic mechanism mediated by TGFbeta-stimulated collagen prolyl hydroxylase expression in fibrotic lung mesenchymal cells. J Pathology. 2015 Jul;236(3):384-94.
  4. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, Kim DS, Kolb M, Nicholson AG, Noble PW, Selman M, Taniguchi H, Brun M, Le Maulf F, Girard M, Stowasser S, Schlenker-Herceg R, Disse B, Collard HR. Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis. New Engl J Med 2014 May 29;370(22):2071-82.
  5. Wettstein G, Bellaye PS, Kolb MRJ, Hammann A, Crestani B, Soler P, Marchal-Somme J, Hazoume A, Gauldie J, Gunther A, Micheau O, Gleave M, Camus P, Garrido C, Bonniaud P. Inhibition of HSP27 blocks fibrosis development and EMT features by promoting snail degradation. FASEB J. 2013 Apr;27(4):1549-60
  6. Farkas L, Ask K, Möller A, Farkas D, Margetts PJ, Gauldie J, Inman M, Kolb MRJ. VEGF-mediated angiogenesis ameliorates pulmonary hypertension in an animal model of lung fibrosis. J Clin Invest 2009;119(5):1298-311
  7. Möller A, Gilpin SE, Ask K, Cox G, Cook DJ, Gauldie J, Margetts PJ, Farkas L, Dobranowski J, Boylan C, O’Byrne PM, Strieter RM, Kolb MRJ. Circulating Fibrocytes are an indicator for poor prognosis in Idiopathic Pulmonary Fibrosis. Am J Resp Crit Care Med 2009; 179(7):588-94